fluorohomoleucine

Fluorohomoleucine (FHL) is a radiolabeled amino acid analog, specifically [18F]fluorohomoleucine, developed as a positron emission tomography (PET) imaging agent. It primarily targets the L-type amino acid transporter 1 (LAT1), also known as SLC7A5, which is frequently upregulated in various malignancies, including multiple myeloma, to support increased metabolic demands and proliferation. Developed through a collaboration involving TRIUMF, BC Cancer, and Simon Fraser University, FHL is designed to provide superior sensitivity and specificity compared to standard [18F]FDG PET in detecting multifocal disease, extramedullary involvement, and bone lesions in multiple myeloma patients. Preclinical studies have demonstrated its ability to visualize tumor engraftment and progression in murine models, correlating tracer uptake with LAT1 expression levels.

Other names

[18F]fluorohomoleucineL-[18F]fluorohomoleucinefluorinated homoleucine